InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
9
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by SHALLCROSS STEVEN A, Chief Executive Officer. Insider active across 3 companies, notably Synthetic Biologics, Inc.. Cumulatively, 10 filings have been logged. Split: 9 buys · 0 sell. Total volume traded: €189k. History available since 10 May 2021. The latest transaction was disclosed on 7 June 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations10 total
14,000 shares@ US$0.69316.1% of flowCommon StockSEC:0001104659-23-069136:0
Ideal exit: 3 Mar 2024 (T+270)
26,000 shares@ US$0.632810.4% of flowCommon StockSEC:0001104659-23-068719:0
Ideal exit: 2 Mar 2024 (T+270)
22,472 shares@ US$0.89100.0% of flowCommon StockSEC:0001017386-23-000063:0
25,000 shares@ US$1.04316.3% of flowCommon StockSEC:0001104659-23-018901:0
Ideal exit: 7 Nov 2023 (T+270)
25,000 shares@ US$0.940514.4% of flowCommon StockSEC:0001104659-23-010108:0
Ideal exit: 30 Oct 2023 (T+270)
25,000 shares@ US$0.87313.5% of flowCommon StockSEC:0001104659-23-006677:0
Ideal exit: 22 Oct 2023 (T+270)
25,000 shares@ US$0.748211.6% of flowCommon StockSEC:0001104659-23-005546:0
Ideal exit: 17 Oct 2023 (T+270)
100,000 shares@ US$0.43727.7% of flowCommon StockSEC:0001104659-23-000023:0
Ideal exit: 25 Sept 2023 (T+270)
50,000 shares@ US$0.491950.0% of flowCommon StockSEC:0001104659-21-064047
Ideal exit: 4 Feb 2022 (T+270)
50,000 shares@ US$0.491950.0% of flowCommon StockSEC:0001104659-21-064047:0
Ideal exit: 4 Feb 2022 (T+270)
10 of 10 declarations
About SHALLCROSS STEVEN A
Steven A. Shallcross is the Chief Executive Officer and Chief Financial Officer of Synthetic Biologics, Inc. He oversees the financial and strategic operations of the company, playing an essential role in growth and innovation.
